Allergan, Inc.

Nuvo Research Inc.

Almirall, LLC

Epi Health, LLC

Aclaris Therapeutics, Inc.

Crescita Therapeutics Inc.

Kevin S Warner

Jie Zhang

Chin-Ming Chang

Richard S Graham

Steven Zhang

Sanjay Sharma

Chetan Pujara

Anuradha V Gore

Pramod Sarpotdar

Gurpreet Ahluwalia

Amy Kuang

Varsha D Bhatt

John T Trogden

Larry D Rigby

R Scott Jordan

Ajay P Parashar

Vijaya Swaminathan

Adnan K Salameh

Sukhon Likitlersuang

Jie Shen

Robert S Jordan

Sesha Neervannan

Kristin B Prinn

Guang Wei Lu

Mu-Lan Lee

Michael A Ashburn

Suyi Niu

Guang Yan

Chetan P Pujara

Jim Jiao

Varsha Bhatt

The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.

Stabilized oxymetazoline formulations and their uses

Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder.

Topical dapsone and dapsone/adapalene compositions and methods for use thereof

Topical dapsone and dapsone/adaplene compositions and methods for use thereof

Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I 

Topical compositions comprising bimatoprost and methods for stimulating hair growth therewith

The present disclosure is drawn to an adhesive peel-forming formulation for dermal delivery of a drug, comprising a drug, a solvent vehicle, and a polymer peel-forming agent. The solvent vehicle can comprise a volatile solvent system comprising one or more volatile solvent, and a non-volatile solvent system comprising two or more non-volatile solvents. The non-volatile solvent system can have a solubility with respect to the drug that is within a window of operable solubility such that the drug is deliverable at therapeutically effective rates over a sustained period of time.

Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same

Compositions and methods for stimulating hair growth

The present invention is drawn to transdermal drug formulations, transdermal patches incorporating such formulations, as well as associated methods. The formulations can include about 0.3 wt % to about 5 wt % of a drug, such as alprazolam, about 4 wt % to about 30 wt % water, about 10 wt % to about 40 wt % glycerol, about 0.5 wt % to about 6 wt % oleyl alcohol. Other co-solvents and/or additives can be present to achieve a 100 wt % formulation.

Patches, formulations, and associated methods for transdermal delivery of alprazolam and other drugs

The present invention is drawn to adhesive peel-forming formulations for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a peel-forming agent. The solvent vehicle can include a volatile solvent system having one or more volatile solvent, and a non-volatile solvent system having one or more non-volatile solvent, wherein the non-volatile solvent system has a solubility for the drug that is within a window of operable solubility for the drug such that the drug can be delivered at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified peelable layer after at least a portion of the volatile solvent system is evaporated.

The present invention is drawn to adhesive solidifying formulations for treating neuropathic pain. The formulation can include a drug suitable for treating neuropathic pain, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.

Compositions and methods for dermally treating neuropathic pain

Growing community of inventors

Anaheim, CA, United States of America

Kevin S Warner